Ride along with Mark as he discusses the danger of intentionally or negligently allowing someone else to use your medical license.
Tag: pharmaceutical
In general terms, the federal Anti-Kickback Statute (“AKS”) prohibits the offer, demand, payment, and acceptance of remuneration—that is, of anything of value—for referrals.
But what about the rising price of settling allegations of pharmaceutical price-fixing?
Many people – physicians and business people – engaging in arrangements involving sophisticated federal and state anti-kickback issues and self-referral issues, often simply point to someone else who is doing what they claim is the same thing, as if that makes it acceptable.
Compounding pharmaceuticals, specific drugs for specific patients, offers tremendous benefit. The problems arise when the benefit is for the prescribing physician.
Former CEO Michael Babich pleaded guilty last week to charges related to the plethora of kickback allegations surrounding Insys Therapeutics, Inc., and its fentanyl drug, Subsys.
U.S. Government Intervenes in 5 Kickback Based Whistleblower Cases Against Insys – Success in Motion
Ride along while Mark discusses the expanding case involving Insys Therapeutics and kickbacks paid to induce prescription of its drug, Subsys.
The federal Anti-Kickback statute makes it illegal to receive anything of value for the referral of federal health care program patients. How are you managing this potential pitfall? Podcast: Play in new window | Download
On October 25, 2017, another physician, Jerrold Rosenberg, M.D., pleaded guilty to charges related to the plethora of kickback prosecutions emanating from Insys Therapeutics, Inc., and its fentanyl drug, Subsys. Couch and Ruan Sent to Prison In February of this year, I wrote in my post Pain Medicine Doctors Alleged to Have Received $115,000 in […]
As I comment often, the federal Anti-Kickback statute makes it illegal to receive anything of value for the referral of federal health care program patients.
